The human microbiome market is projected to reach USD 1.7 billion by 2029 from USD 0.3 billion in 2023, at a CAGR of 36.1% during the forecast period. The key factors driving the growth of the global human microbiome market are collaborative efforts between microbiome industry and academia for microbiome research, and rising awareness about importance of human microbiome. However, the adverse impact of complex regulatory policies on commercialization of microbiomes are expected to restrain market growth to a certain extent.
The market for human microbiome is highly consolidated, with key players strategizing to capture majority of the market. Prominent players in the market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc. (US), YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).
To know about the assumptions considered for the study download the pdf brochure
Seres Therapeutics, Inc. (US)
Seres Therapeutics focuses on developing microbiome therapeutics for treating diseases related to dysbiosis. The firm has a strong pipeline of products in various stages of development, including SER-109, which is aimed at treating recurrent Clostridium difficile infection (CDI), and SER-287, which is being developed for the treatment of inflammatory bowel disease (IBD).
Another factor contributing to Seres Therapeutics' leadership in the microbiome market is its innovative technology platform, which combines bioinformatics, machine learning, and high-throughput DNA sequencing to identify potential therapeutic candidates from the human microbiome. This platform allows the company to develop targeted therapies that are designed to restore the natural balance of the microbiome and improve patient outcomes.
Seres Therapeutics also has several strategic partnerships and collaborations with leading pharmaceutical companies and academic institutions, which provide access to additional resources, expertise, and funding. For example, the company has a collaboration agreement with Nestlé Health Science for the development of microbiome-based therapies for CDI and IBD, as well as a collaboration with Memorial Sloan Kettering Cancer Center for the development of microbiome therapeutics for cancer.
Overall, Seres Therapeutics' focus on developing microbiome therapeutics for the treatment of dysbiosis-related diseases, innovative technology platforms, and strategic partnerships have contributed to its leadership in the microbiome market.
Enterome is a key market player in the human microbiome market due to its innovative approach to developing microbiome-based therapies and diagnostics. It is developing a pipeline of microbiome-based diagnostic tests. These tests use microbial biomarkers to aid in the diagnosis and monitoring of various diseases, including inflammatory bowel disease, colon cancer, and liver diseases.
Enterome has also established several strategic partnerships to further advance its research and development efforts. For example, since 2016, the company has been partnering with Takeda Pharmaceuticals to develop microbiome-based therapeutics for the treatment of inflammatory bowel disease. In 2022, the company partnered with Nestlé Health Science to develop microbiome-based diagnostics and therapeutics.
4D pharma plc (UK)
4D pharma plc is one of the key players in the human microbiome market due to its innovative approach toward the development of microbiome-based therapies. The company uses a unique platform technology called MicroRx, which allows it to identify, isolate, and culture live bacteria from the gut microbiome. This approach enables the company to develop precise and targeted therapies for specific diseases by selecting and isolating beneficial bacteria that have a therapeutic effect.
Moreover, 4D Pharma has a strong pipeline of microbiome-based therapies in various stages of development, including Phase II and Phase III clinical trials for the treatment of conditions such as irritable bowel syndrome, cancer, and asthma. In addition, the company collaborates with major pharmaceutical companies such as MSD and AstraZeneca, which provides it with access to their expertise and resources.
Furthermore, 4D Pharma has a strong intellectual property portfolio, with numerous patents related to its MicroRx technology and microbiome-based therapies. The company's patents cover various aspects of microbiome therapy development, including methods for selecting and isolating beneficial bacteria and formulations for delivering these bacteria to the gut.
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE